首页> 外文OA文献 >The TeaM (Therapeutic Mammaplasty) Study:Protocol for a prospective multi-centre cohort study to evaluate the practice and outcomes of therapeutic mammaplasty
【2h】

The TeaM (Therapeutic Mammaplasty) Study:Protocol for a prospective multi-centre cohort study to evaluate the practice and outcomes of therapeutic mammaplasty

机译:TeaM(治疗性乳房成形术)研究:一项前瞻性多中心队列研究的协议,以评估治疗性乳房成形术的实践和结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Wide local excision and adjuvant radiotherapy is the standard of care for early breast cancer. For large tumours, however, mastectomy is frequently recommended as conventional breast-conserving techniques often result in poor cosmetic outcomes. Therapeutic mammaplasty (TM) may extend the boundaries of breast-conserving surgery by combining breast reduction and mastopexy techniques with tumour excision, preserving a natural breast shape and avoiding the need for mastectomy. The prevalence of this operative option among surgeons in the UK and its success rate are unknown. The TeaM study is a multicentre prospective study that aims to investigate the practice and outcomes of TM. Breast centres performing TM will be invited to participate through the research collaborative network and the professional associations. All patients undergoing TM between September 2016 and March 2017 will be included. Demographic, operative, oncological and complication data within 30-days of surgery will be collected. The primary outcome will be unplanned re-operation for complications. Secondary outcomes will include unplanned readmission, re-excision rates and time to adjuvant therapy. Prospective data on 500 patients from 50 centres is anticipated. Exploratory analyses will identify predictors for complications and inform the design of a definitive study.Research ethics approval is not required for this study. This has been confirmed by the on-line Health Research Authority decision tool. This study will provide novel information regarding the practice and outcomes of TM in the UK. This will inform decision-making for patients and surgeons and inform future research. Dissemination of the study protocol will be via the Mammary Fold Academic and Research Collaborative, the Reconstructive Surgery Trials Network and the professional associations, the Association of Breast Surgery and British Association of Plastic, Reconstructive and Aesthetic Surgeons. Results will be presented at relevant surgical conferences and published in peer-reviewed journals.
机译:广泛的局部切除和辅助放疗是早期乳腺癌的治疗标准。但是,对于大肿瘤,通常建议行乳房切除术,因为常规的保乳技术通常会导致不良的美容效果。乳腺成形术(TM)可通过将乳房缩小术和乳房畸形术与肿瘤切除术相结合,保留自然的乳房形状并避免进行乳房切除术来扩大保留乳房的手术的范围。在英国外科医生中这种手术选择的普遍性及其成功率尚不清楚。 TeaM研究是一项多中心前瞻性研究,旨在研究TM的实践和结果。执行TM的乳房中心将通过研究合作网络和专业协会被邀请参加。包括2016年9月至2017年3月期间接受TM的所有患者。将收集手术后30天内的人口统计学,手术,肿瘤学和并发症数据。主要结果将是因并发症而计划外的再次手术。次要结果将包括计划外的再次入院,再次切除率和辅助治疗时间。预计将有来自50个中心的500名患者的前瞻性数据。探索性分析将确定并发症的预测因素,并为确定性研究的设计提供信息。该研究不需要研究伦理学的批准。在线健康研究局决策工具已证实了这一点。这项研究将提供有关TM在英国的实践和结果的新颖信息。这将为患者和外科医生的决策提供依据,并为将来的研究提供依据。研究方案的传播将通过乳腺折叠学术和研究合作组织,重建外科手术试验网络以及专业协会,乳腺癌外科协会和英国整形,重建和美容外科医师协会进行。研究结果将在相关的外科会议上发表,并发表在同行评审的期刊上。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号